Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC)

Similar Items

• Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: A matching-adjusted indirect comparison
  by: Fautrel, B, et al.
  Published: (2020)
• Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
  by: Alison O’Mahony, et al.
  Published: (2018-06-01)
• Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM
  by: Fautrel, B, et al.
  Published: (2019)
• Baricitinib versus placebo or adalimumab in rheumatoid arthritis
  by: Taylor, P, et al.
  Published: (2017)
• Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib
  by: Fautrel, B, et al.
  Published: (2017)